A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2025-08-10
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC combined with AK104
in perioperative treatment of muscle-invasive bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences